The U.S. initial public offering market has crossed a significant milestone in 2026: 100 deals completed by mid-April, running 6.38% ahead of 2025’s pace at the same point in the calendar, according to data from StockAnalysis. With geopolitical headwinds easing and risk appetite returning, the IPO window — long squeezed by rate uncertainty and market volatility — appears to be reopening in earnest.
The proximate catalyst is familiar by now: Middle East de-escalation. Iran’s announcement this week that it would reopen the Strait of Hormuz following a ceasefire framework with the United States sent equity markets to fresh record highs and pushed crude oil below $90 per barrel. For IPO markets, the significance runs deeper than headlines. Reduced geopolitical uncertainty typically compresses the risk premium investors demand on new, unproven public companies. When that premium falls, underwriting windows open.
Biotech Is Leading the Charge
The sector showing the most consistent first-day strength in 2026 is biotechnology. Kailera Therapeutics debuted on the Nasdaq this week with shares jumping 62.5% on its opening session — one of the year’s strongest biotech debuts. The company, focused on next-generation cardiometabolic treatments, priced at the high end of its expected range before trading commenced.
It is not alone. Veradermics, a dermatology-focused therapeutics company, has surged 352% since its February offering at $17 per share, now trading near $76 (StockAnalysis, April 2026). SpyGlass Pharma has climbed 55% from its $16 IPO price in February.
The pattern reflects a broader theme: investors are willing to price growth and optionality into biotech names when the macro environment feels stable. With the Federal Reserve holding its benchmark rate steady through the first quarter of 2026 and the risk-off impulse receding, biotech’s inherently long-duration cash flows become more palatable to institutional allocators.
Defense and Drone Names Join the Party
Outside biotech, defense-adjacent technology companies are finding receptive audiences. AEVEX Aerospace, a drone systems manufacturer, rose 15% in its NYSE debut this week. The gain is more modest than the biotech pops, but meaningful for a sector that was largely shut out of public markets during the 2022–2023 rate shock.
The drone sector’s emergence on public markets reflects structural shifts in defense procurement. NATO allies are accelerating spending, unmanned systems have proved their operational value in Eastern European theaters, and U.S. Department of Defense contracts for autonomous platforms continue to expand. These factors provide the narrative scaffolding investors need to underwrite growth-stage defense technology companies at premium multiples.
The Standouts — and the Stumbles
Not every 2026 IPO has been a winner, and the market remains bifurcated. Swarmer Inc. (SWMR), a software company that priced at $5 per share in March, has rocketed 654% — but micro-cap IPOs priced near penny-stock territory often reflect thin floats and speculative trading rather than institutionally underwritten conviction. Extreme first-day or first-month moves in these names do not signal broad market health on their own.
On the flip side, BitGo Holdings — the crypto custody firm that had been one of the most anticipated listings of 2026 — has declined 41% from its $18 IPO price. The crypto sector remains polarizing for institutional allocators navigating regulatory uncertainty, and BitGo’s stumble is a reminder that favorable macro conditions do not immunize every new listing from execution risk or sector-specific headwinds.
AGI Inc., another small-cap offering, has lost 35% of its offering value, further underscoring that 2026’s IPO environment rewards quality and punishes stretch valuations.
What’s Coming: X-Energy and Pershing Square
The remainder of April includes two high-profile offerings that will serve as meaningful tests of investor appetite.
X-Energy (XE), scheduled to list on April 24, is a nuclear microreactor company backed by Ares Management and supported by U.S. Department of Energy loan guarantees. The company is developing advanced modular reactors for commercial and industrial customers — a story at the intersection of clean energy, national security, and the exploding power demand from AI data centers. Institutional interest has been significant, positioning this deal as a litmus test for how public markets value next-generation nuclear infrastructure.
Pershing Square (PS), scheduled to begin trading on April 29, is a vehicle tied to hedge fund manager Bill Ackman that has been positioned partly as a retail-accessible investment in his fund’s strategies. The offering structure and its retail-facing design make it one of the more unconventional IPOs of the year — and a closely watched signal for whether high-profile fund managers can successfully translate institutional track records into public market valuations.
Three Macro Forces Shaping the Window
Rate Stability
The Federal Reserve has held its benchmark rate steady through Q1 2026, and while the forward path remains debated, the absence of sharp rate surprises has allowed underwriters to price deals with greater confidence. Predictable rates reduce the discount rate uncertainty that hammered growth-stock valuations in 2022 and cooled IPO activity through much of 2023 and 2024.
Equity Market Momentum
Bull markets historically provide favorable windows for IPOs. Rising indices reduce the relative attractiveness of staying private, improve pricing leverage for selling shareholders, and increase the likelihood that post-IPO trading performance will hold above offer price — a critical factor for maintaining underwriter relationships and encouraging future listings.
The Unicorn Backlog
An estimated 500-plus private companies globally hold valuations above $1 billion. Many delayed going public through 2022–2024 as equity markets were turbulent and valuation marks from private rounds proved difficult to defend in public market comps. The combination of stable rates and rising equities is creating pressure to clear that backlog. Bankers are actively pushing companies toward the finish line, and venture and private equity sponsors — facing aging fund cycles — are increasingly motivated to realize returns.
Risks to Watch
The optimism is not without caveats. Tariff uncertainty — the U.S.-China trade relationship remains in flux, with multiple sectors facing evolving import costs — creates earnings visibility challenges for consumer-facing and industrial companies contemplating listings. Companies with significant international supply chains may continue to wait for greater clarity before committing to the roadshow process.
Geopolitical risk, while reduced this week, is not eliminated. A reversal in the Middle East situation or fresh flashpoints could quickly re-tighten credit spreads and damp IPO appetite, as markets have demonstrated multiple times in the past 24 months.
Valuation discipline also remains a risk in its own right. In a rising market, the temptation for issuers to stretch pricing relative to comparables is significant. Deals that price aggressively and then underperform — as BitGo has demonstrated — tend to have a chilling effect on the broader IPO calendar, as institutional allocators grow more selective about where they commit capital.
The Bottom Line
With 100 IPOs completed through mid-April and a pipeline of ambitious listings ahead, 2026 is shaping up as the year the post-2022 IPO drought finally clears. Biotech, defense technology, and clean energy are leading the charge, supported by a macro environment that — for now — is cooperating. The key question for the next 60 days is whether the tailwinds of rate stability, geopolitical calm, and rising equities hold long enough to bring the unicorn backlog to market in scale.
Disclosure: This article was produced with AI assistance and reviewed before publication. It is for informational purposes only and is not investment advice.